ZA200106113B - Methods and compositions for healing and repair of articular cartilage. - Google Patents
Methods and compositions for healing and repair of articular cartilage. Download PDFInfo
- Publication number
- ZA200106113B ZA200106113B ZA200106113A ZA200106113A ZA200106113B ZA 200106113 B ZA200106113 B ZA 200106113B ZA 200106113 A ZA200106113 A ZA 200106113A ZA 200106113 A ZA200106113 A ZA 200106113A ZA 200106113 B ZA200106113 B ZA 200106113B
- Authority
- ZA
- South Africa
- Prior art keywords
- bmp
- graft
- tissue
- osteochondral
- articular cartilage
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 27
- 210000001188 articular cartilage Anatomy 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title description 15
- 230000008439 repair process Effects 0.000 title description 14
- 230000035876 healing Effects 0.000 title description 7
- 210000001519 tissue Anatomy 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 15
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 15
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 15
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 8
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 8
- 230000002188 osteogenic effect Effects 0.000 claims description 8
- 230000010354 integration Effects 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims description 4
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- 101710167839 Morphogenetic protein Proteins 0.000 claims 2
- 230000003848 cartilage regeneration Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 description 19
- 230000007547 defect Effects 0.000 description 16
- 239000003102 growth factor Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 206010061762 Chondropathy Diseases 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 206010007710 Cartilage injury Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 241000282553 Macaca Species 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005065 subchondral bone plate Anatomy 0.000 description 3
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008558 Osteophyte Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000002648 chondrogenic effect Effects 0.000 description 2
- 239000000515 collagen sponge Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 101100175313 Mus musculus Gdf3 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003707 glutamic acid hydrochloride Drugs 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- -1 include BMP-12 Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
Description
} METHODS AND COMPOSITIONS FOR HEALING AND
REPAIR OF ARTICULAR CARTILAGE
The present invention relates to the field of tissue repair, specifically, the regeneration of stable and functional articular cartilage repair. Thus, the present invention may be useful in reconstructive surgery or other procedures for the regeneration or repair of articular cartilage. :
The repair of articular cartilage injuries remains a challenge in present day orthopedics. Several of the current therapeutic strategies are based upon the grafting of chondral and osteochondral tissues. Autologous osteochondral grafting provides the most appropriate physiological material. However, donor tissue is limited, and often requires . surgery at a secondary site in order to harvest tissue for transplant. Accordingly, despite substantial endeavors in this field, there remains a need for an effective method of repair i of articular cartilage defects and injuries which provides appropriate physiological repair without the need to collect autologous tissue from the patient.
The present invention provides methods and compositions for regenerating functional and physiologically appropriate tissue repair for the repair of articular cartilage injuries and defects. In particular, the present invention comprises methods of treating patients with articular cartilage injuries or defects. The methods and compositions of the present invention are advantageous in that they utilize bone morphogenetic proteins : (BMPs), which are known to have osteogenic and/or chondrogenic properties, and which may be produced via recombinant DNA technology, and therefore are of potentially unlimited supply. The methods and compositions of the present invention are further advantageous in that regeneration of functional articular cartilage may be accelerated or may be of greater ultimate strength and stability, and the tissue formed at the site of the defect or injury is physiologically appropriate. '
The use of BMP to augment the repair of articular cartilage defects and injuries may result in better methods for treatment of osteoarthritis, thus obviating, delaying or ’ reducing the need for artificial hip replacements and other common interventions.
Preclinical evaluations indicate that thBMP-2 improves early healing of full thickness defects of articular cartilage in rabbits.
According to the present invention, methods and compositions are provided for treatment of patients who suffer from some form of articular cartilage injury or defect.
The injury may be the result of acute stress, or injury, such as resulting from participation in athletics, or from accidental occurrences which tear, mar or otherwise injure the articular cartilage.
The methods and composition are advantageous in that repair or improvement of articular cartilage defects, particularly full thickness articular cartilage defects. Other defects may also be treated by the methods and compositions of the present invention, ’ particularly with an additional procedure in which the site of the defect is further : aggravated so as to reach the underlying subchondral bone. :
In the present invention, active growth factor, such as a BMP, is added toa suitable tissue source. The tissue source may be an osteochondral graft, either autologous to the patient, or may comprise allograft or artificially prepared tissue. In a preferred - embodiment, the tissue source may be chondrocytic cell cultures, such as chondrocyte or stem cell cultures which have been prepared through ex vivo cell culture methods, with or without additional growth factors. For example, see the disclosure of US5226914;
US5811094; US5053050; US5486359; US5786217 and US5723331. The disclosures of all of these applications are hereby incorporated herein by reference.
The tissue may also be harvested by traditional non-cell culture based means, using techniques such as mosaicplasty, in which cartilage is harvested using commercially available instruments such as Acufex7 [Smith and Nephew, Inc., Andover MA]; COR
System [Innovasive Technologies, Marlborough MAJ]; or Arthrex7 Osteochondral
Autograft Transfer System [Arthrex, Munich, Germany]. The tissue harvested may be applied directly in the methods of the present invention, or may be combined with the tissue based cell culture systems described above.
GROWTH FACTOR
The active growth factor used in the present invention is preferably from the subclass of proteins known generally as bone morphogenetic proteins (BMPs), which have been disclosed to have osteogenic, chondrogenic and other growth and differentiation type activities. These BMPs include thBMP-2, thBMP-3, rhBMP-4 (also referred to as thBMP-2B), rhBMP-5, thBMP-6, thBMP-7 (thOP-1), rhBMP-8, thBMP-9, rhBMP-12, thBMP-13, thBMP-15, thBMP-16, thBMP-17, thBMP-18, thGDF-1, thGDF- 3, thGDF-5, thGDF-6, thGDF-7, thGDF-8, rhGDF-9, thGDF-10, thGDF-11, thGDF-12, thGDF-14. For example, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7, : disclosed in United States Patents 5,108,922; 5,013,649; 5,116,738; 5,106,748; 5,187,076; ’ and 5,141,905; BMP-8, disclosed in PCT publication W0O91/18098; and BMP-9, disclosed in PCT publication W(093/00432, BMP-10, disclosed in United States Patent - 5,637,480; BMP-11, disclosed in United States Patent 5,639,638, or BMP-12 or BMP-13, disclosed in United States Patent 5,658,882, BMP-15, disclosed United States Patent : 5,635,372 and BMP-16, disclosed in co-pending patent application serial number 08/715,202. Other compositions which may also be useful include Vgr-2, and any of the growth and differentiation factors [GDFs], including those described in PCT applications
WO094/15965; W0O94/15949; W095/01801; W(Q95/01802; WO94/21681; W(O94/15966;
WO095/10539; WO096/01845; W096/02559 and others. Also useful in the present invention may be BIP, disclosed in W094/01557; HP00269, disclosed in JP Publication number: 7-250688; and MP52, disclosed in PCT application W093/16099. The disclosures of all of these applications are hereby incorporated herein by reference. Also useful in the present invention are heterodimers of the above and modified proteins or partial deletion products thereof. These proteins can be used individually or in mixtures of two or more, and thBMP-2 is preferred. i
The BMP may be recombinantly produced, or purified from a protein composition.
The BMP may be homodimeric, or may be heterodimeric with other BMPs (e.g, a heterodimer composed of one monomer each of BMP-2 and BMP-6) or with other members of the TGF-B superfamily, such as activins, inhibins and TGF-f1 (e.g., a heterodimer composed of one monomer each of a BMP and a related member of the TGF-
B superfamily). Examples of such heterodimeric proteins are described for example in
Published PCT Patent Application WO 93/09229, the specification of which is hereby incorporated herein by reference. The amount of osteogenic protein useful herein is that amount effective to stimulate increased osteogenic activity of infiltrating progenitor cells, and will depend upon the size and nature of the defect being treated, as well as the carrier being employed. Generally, the amount of protein to be delivered is in a range of from about 0.05 to about 1.5 mg.
In a preferred embodiment, the osteogenic protein is administered together with an effective amount of a protein which is able to induce the formation of tendon- or ligament-like tissue. Such proteins, include BMP-12, BMP-13, and other members of the :
BMP-12 subfamily, as well as MP52. These proteins and their use for regeneration of tendon and ligament-like tissue are disclosed in United States application serial number - serial number 08/362,670, filed on December 22, 1994, the disclosure of which is hereby incorporated herein by reference. In another preferred embodiment, a heterodimer in which one monomer unit is an osteogenic protein such as BMP-2, and the other monomer subunit is a tendon-inducing protein, such as BMP-12, is administered in accordance with the methods described below, in order to induce the formation of a functional attachment between connective tissue and bone.
APPLICATION OF GROWTH FACTOR
: Growth factor may be applied to the tissue source in the form of a buffer solution.
One preferred buffer solution is a composition comprising, in addition to the active growth factor, about 1.0 to about 10.0% (w/v) glycine, about 0.1 to about 5.0% (w/v) of a sugar, preferably sucrose, about 1 to about 20 mM glutamic acid hydrochloride, and optionally about 0.01 to about 0.1% of a non-ionic surfactant, such as polysorbate 80.
Preferred solutions are from about 1% to about 20% w/v cellulosic carrier/buffer. If desired, a salt may be added.
Other materials which may be suitable for use in application of the growth factors in the methods and compositions of the present invention include hyaluronic acid, surgical mesh or sutures, polyglyconate, temperature-sensitive polymers, demineralized bone, minerals and ceramics, such as calcium phosphates, hydroxyapatite, etc., as well as combinations of the above described materials. In the preferred embodiment of the : present invention, however, no carrier is employed. . . The growth factor of the present invention, in a suitable buffer such as that described above, or combined with a suitable carrier, may be applied directly to the tissue . and/or to the site in need of tissue repair. For example, the growth factor may be physically applied to the tissue through spraying or dipping, or using a brush or other suitable applicator, such as a syringe for injection. Alternatively, or in conjunction, the protein may be directly applied to the site in need of tissue repair.
The following examples further describe the practice of embodiments of the invention with BMP-2. The examples are not limiting, and as will be appreciated by those skilled in the art, can be varied in accordance with the above specification.
I. Rabbit Allograft -
All procedures were carried out with approval from JACUC. Twelve male New
Zealand white rabbits (6 months old) were used. Two rabbits served as donors and 10 as recipients. Osteochondral grafts (3.5 mm diameter) were harvested from the trochlear groove or the medial femoral condyle of the donors, and transplanted into a 3.5 mm deep defect in the trochlear groove of the recipient. The graft was bathed in either hBMP-2 (0.5 mg/ml) or buffer control prior to implantation. The rabbits were sacrificed 4 weeks : after surgery and the transplants and surrounding tissue were evaluated by a histologic- histochemical grading scale, as described in Sellers et al., J. Bone Joint Surg., 79-A:1452- 1463 (1997). Computerized image analysis of histologic sections was also performed.
Results were evaluated using the unpaired Students t-test.
On gross examination, the joints showed no signs of inflammation. All the defects were filled by repair tissue. The surface appearance of the defects was variable but acceptable and did not correlate with form of treatment. Osteophytes were found in 3 } joints (2 in the experimental group; 1 in control buffer group). oo
There was no correlation between the gross and histologic appearance in any of ’ the defects. The presence of chondrocytes in the lacunae and sporadic cloning of cells in the donor cartilage indicated survival of the tissue. Focal degeneration of the donor . cartilage was present in all of the control groups, but only one of the thBMP-2 treated group. The healing of the defect in the rhBMP-2 treated group was significantly improved compared to that in the control group. The rhBMP-2 treated group had improved bony integration indicated by less fibrous repair tissue in the subchondral bone compartment. Treatment with thBMP-2 also resulted in more cartilage above the original tidemark, apparently consisting of both donor tissue and newly regenerated recipient cartilage. There was no significant difference in the total amount of bone observed between the two groups.
TABLE I
HISTOLOGIC SCORE AND HISTOMORPHOMETRIC MEASUREMENT
FOR CARTILAGE REPAIR, MEAN VALUE (SD) 0 © * Statistically significant difference from control (p<0.05). ** Scale system ranges from O (normal cartilage) to 31 (no repair).
Additional histomorphometric analysis data further supports the beneficial effects of thBMP-2 on the healing of graft. For example, the percentage filling of the new tissue above tide marker has been shown to be 81.52% in a thBMP-2 treated group vs. 57.63% in control. There was less graft cartilage degeneration in thBMP-2 treated group (23.83%) than in control group (44.52%). The integration of the graft or newly formed cartilage with the host cartilage was improved by thBMP-2 weatment (56.48%) compared to that of control group (21.89%). More new cartilage formed under the influence of rhBMP-2 either at the edge of graft, which eliminated the gap between the graft and host, or at the top of graft, which made the graft more congruent with the joint surface.
The above results demonstrate that the healing of allogeneic osteochondral grafts in articular cartilage defects was improved by the addition of thBMP-2. The active growth factor may have accelerated subchondral bone union, providing support and nutrition to the articular cartilage tissue. Addition of growth factor may also have stimulated new cartilage formation from recipient mesenchymal stem cells in the bone marrow and/or the synovial tissue. These results suggest that the combination of active growth factor, particularly the bone morphogenetic proteins, and osteochondral allografts might present a potent strategy for treatment of articular cartilage defects, particularly full thickness articular cartilage defects.
I0. Rabbit Autograft
Osteochondral grafts (2.7 mm in diameter and 3.0 mm long) were harvested from the trochlear groove or femoral condyle and transplanted into a donor site 2.7mm wide and 3.5mm long on the trochlear groove or femoral condyle of the knee joint in rabbits.
Half the animals had buffer dripped into the recipient site prior to transplantation, and then the grafts were dipped in buffer for 2 minutes and placed into the recipient site. The other half had Spg rhBMP-2 dripped into the recipient site prior to transplantation, and then the graft was dipped into buffer containing 500pg/m} thBMP-2 for 2 minutes and then transplanted into the recipient site. The animals were sacrificed 4 weeks after surgery, and the recipient sites were evaluated histologically using both a histologic- histochemical grading scale [Sellers, et al., J. Bone Joint Surg., 79-A: 1452-63 (1997)] and quantitative computerized image analysis of the tissue. The data indicated that treatment with thBMP-2 improved the healing of the autograft. The most dramatic effects were the reduction of graft cartilage degeneration (thBMP-2 8.18% vs. control 36.25%), and more cartilage formed at the edge of graft (thBMP-2 88.23% vs. control 50%).
III. Non-Human Primate Autograft: so
The non human primates used for autografts experiments were cynomologous macaques. Osteochondral grafts (3.5mm diameter x 6mm long) were harvested from the trochlear groove of 6 cynomologous macaques and transplanted into recipient sites drilled into both the medial and lateral femoral condyle of the same animal (n=12 transplants total). Prior to transplantation 25ug rhBMP-2 was dripped into 6 recipient sites, and the grafts from those 6 transplants were dipped into a solution of 1.25mg/mil thBMP-2 for 2 minutes. In the other 6 transplants, buffer alone was dripped into the recipient sites and ~~ the grafts were dipped into buffer alone for 2 minutes prior to transplantation. The limbs were immobilized in a cast for 2 weeks post-operatively, and the animals were sacrificed 9 weeks post operatively.
All the animals had normal function of their knee joints. On gross examination, the joints showed no signs of inflammation. Osteophytes were not found in any joint. ' Although the surface of the defects appeared level with the surrounding cartilage on gross examination, microscopic observation revealed subsidence of the grafts in most of the cases. The tissue observed grossly covering the surface was actually new-formed tissue on the top of graft. Computerized image analysis was performed by a blinded evaluator to quantitate percent filling of the defect, the new tissue types formed above the original tide mark, and the integration of the grafts and the surrounding cartilage. Favorable results were observed in the thBMP-2 treated group in all these parameters. More new cartilage formed between the graft and host cartilage to eliminate the gap resulting in better integration of the graft with the surrounding cartilage (thBMP-2 88.59% vs. control 64.82%). The filling of the cartilage defect was better in rhBMP-2 treated group (95.02%) than in the control group (86.68%). There was more fibrous tissue in the control group (11.90% vs. thBMP-2 5.65%), while more transitional tissue was found in the thBMP-2 treated group (36.38% vs. control 20.53%). There was no significant difference on the : 20 overall histologic-histochemical score between the two groups. Peripheral quantitative computered tomography (pQCT) showed that the bone density increased in the donor sites . with time. At 6 weeks and 9 weeks after the operation, the tissue in the rhBMP-2 treated donor sites was significantly denser and the healing process was more advanced compared to control sites. Histologically, the donor sites contained regenerated bone trabeculae with fibrous tissue at the surface in all the cases. ¢
IV. rhBMP-2 Retention Ex Vivo:
Retention of thBMP-2 in osteochondral graft with this technique was evaluated with the grafts from non-human primates. The graft was dipped in a mixture solution of 121 1abeled thBMP-2 and unlabeled thBMP-2. Results showed that the amount of thBMP- 2 absorbed to graft was proportional to the concentration of the protein, and the time of soaking. Other factors, which affect the retention of thBMP-2, included the size of graft, and the presence of marrow elements between trabecular bone.
: CL ’ i o ;
V. rhBMP-2 Retention Time Course In Vivo:
The time course of rhBMP-2 retention in osteochondral graft was evaluated in ' rabbits. A mixture solution of '¥I labeled thBMP-2 and unlabeled rhBMP-2, which contained 5 ug thBMP-2 and 20 uCi I, was loaded to the graft before implantation. The animals were scanned with y-camera during the follow-up time for 22 days post- operatively. Compared to the time course of collagen sponge as a carrier, the half time of rthBMP-2 in osteochondral graft was increased from 1 day to 3 days. The radioactivity of 10% of the starting point was maintained from 11 days of collagen sponge to 22 days of graft.
VI. Non-Human Primate Allografts:
Donor sites (3.5 mm wide x 6 mm long) were removed from the trochlear grooves of 12 adult cynomologous macaques and transplanted into 3.5 x 6mm recipient sites in the medial and lateral femoral condyles of unrelated individuals. Half of the transplants were soaked in 1.25 mg/ml rhBMP-2 for 2 minutes prior to transplantation, and half were . soaked in buffer. The identical procedure was performed on the other limb 7 weeks after the first surgery. The limb was immobilized in a cast for 2 weeks post operatively after . each surgery, and the animals were sacrificed 9 weeks after the second surgery for histologic analysis.
These results suggest that the combination of active growth factor, particularly the bone morphogenetic proteins, and osteochondral autografts might present a potent strategy for treatment of articular cartilage defects, particularly full thickness articular cartilage defects. In other embodiments BMP-2 may also be applied to frozen osteochondral allograft for treatment of focal articular cartilage defect.
The foregoing descriptions detail presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descriptions. Those modifications and variations are believed to be encompassed within the claims appended hereto.
Claims (17)
1. An osteochondral graft for administration to an area in need of articular cartilage regeneration having applied thereto an effective amount of bone morphogenetic protein (BMP) to stimulate osteogenic activity of infiltrating progenitor cells.
2. An osteochondral graft according to claim 1, wherein said graft is an allograft.
3. An osteochondral graft according to claim 1, wherein said graft is an autograft.
4. An osteochondral graft according to any one of claims 1 to 3, wherein about 0.05 to about 1.5 mg of BMP is applied thereto.
5. An osteochondral graft according to any one of claims 1 to 4, wherein said BMP is BMP-2.
6. An osteochondral graft according to any one of claims 1 to 5, having further applied thereto an effective amount of a protein which induces the formation of tendon or ligament tissue, wherein said protein is selected from the group consisting of BMP- 12, BMP-13 and MP-52.
7. A process for preparing an osteochondral graft for administration to an area in need of regeneration of articular cartilage, wherein said process comprises; 6) harvesting an osieochondral graft tissue source; (it) applying to the tissue source an effective amount of at least one purified bone morphogenetic protein (BMP) to stimulate osteogenic activity of infiltrating progenitor cells, AMENDED SHEET
\ PCT/US00/02430 i 12-
8. A process according to claim 7, wherein said tissue source is an allograft.
9. A process according to claim 7, wherein said tissue source is an autograft.
10. A process according to any one of claims 7 to 9, wherein step (ii) comprises applying to the tissue source from about 0.05 to about 1.5 mg of BMP.
11. A process according to any one of claims 7 to 10, wherein said BMP is selected from the group consisting of BMP-12, BMP-13 members of the BMP-12 subfamily and BMP-2.
12. A process according to any one of claims 7 to 10, wherein said BMP is BMP-2.
13. Use of at least one purified morphogenetic protein (BMP) in the preparation of a medicament for improving integration of an osteochondral graft when administered therewith to an area in need of articular cartilage regeneration.
14. A graft according to claim 1, substantially as herein described and illustrated.
15. A process according to claim 7, substantially as herein described and illustrated.
16. Use according to claim 13, substantially as herein described and illustrated.
17. A new graft, a new process for preparing a graft, or a new use of at least one purified morphogenetic protein (BMP), substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11816099P | 1999-02-01 | 1999-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200106113B true ZA200106113B (en) | 2002-11-12 |
Family
ID=22376840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200106113A ZA200106113B (en) | 1999-02-01 | 2001-07-25 | Methods and compositions for healing and repair of articular cartilage. |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100704537B1 (en) |
| CN (2) | CN100435859C (en) |
| ZA (1) | ZA200106113B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101012869B1 (en) * | 2008-02-05 | 2011-02-08 | 동국대학교 산학협력단 | Chondrogenesis of bone marrow mesenchymal stem cells |
| US20180000736A1 (en) * | 2015-01-08 | 2018-01-04 | University Of Iowa Research Foundation | Methods for the regeneration of articular cartilage in vivo |
| CN106031792A (en) * | 2015-03-10 | 2016-10-19 | 西比曼生物科技（上海）有限公司 | Composition for treating defects of articular cartilage |
| WO2017151674A1 (en) * | 2016-02-29 | 2017-09-08 | Cedars-Sinai Medical Center | Method of endogenous stem cell activation for tendon/ligament osseointegration |
| US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| US5770209A (en) * | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
| US5902785A (en) * | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
| WO1998031788A1 (en) * | 1997-01-21 | 1998-07-23 | Genetics Institute, Inc. | Injectable formulations for treatment of osteoporotic bone |
-
2000
- 2000-01-31 KR KR1020017009650A patent/KR100704537B1/en not_active IP Right Cessation
- 2000-01-31 CN CNB008055386A patent/CN100435859C/en not_active Expired - Fee Related
- 2000-01-31 CN CNA2008101693859A patent/CN101385851A/en active Pending
-
2001
- 2001-07-25 ZA ZA200106113A patent/ZA200106113B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1345251A (en) | 2002-04-17 |
| KR100704537B1 (en) | 2007-04-09 |
| CN100435859C (en) | 2008-11-26 |
| KR20010101897A (en) | 2001-11-15 |
| CN101385851A (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6727224B1 (en) | Methods and compositions for healing and repair of articular cartilage | |
| EP0831884B1 (en) | Use of bone morphogenic proteins for healing and repair of connective tissue attachment | |
| EP1148897B1 (en) | Methods and compositions for healing and repair of articular cartilage | |
| WO1998051354A2 (en) | Compositions for morphogen-induced osteogenesis | |
| KR100704537B1 (en) | Compositions for healing and repair of articular cartilage | |
| MXPA01007731A (en) | Methods and compositions for healing and repair of articular cartilage | |
| AU2006275444A1 (en) | Methods and compositions for regenerating articular cartilage | |
| Hecht et al. | Advances in the Biology of Spinal Fusion: Growth Factors and Gene Therapy |